Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
9.68
Dollar change
+0.06
Percentage change
0.62
%
IndexRUT P/E- EPS (ttm)-5.65 Insider Own17.81% Shs Outstand96.79M Perf Week21.46%
Market Cap936.93M Forward P/E- EPS next Y-2.60 Insider Trans0.46% Shs Float79.55M Perf Month112.28%
Income-311.46M PEG- EPS next Q-0.78 Inst Own97.01% Short Float21.09% Perf Quarter412.17%
Sales3.69M P/S253.91 EPS this Y30.77% Inst Trans12.23% Short Ratio2.87 Perf Half Y28.72%
Book/sh0.76 P/B12.82 EPS next Y33.55% ROA-72.65% Short Interest16.78M Perf Year-39.00%
Cash/sh2.36 P/C4.11 EPS next 5Y9.80% ROE-122.80% 52W Range1.76 - 17.57 Perf YTD199.69%
Dividend Est.- P/FCF- EPS past 5Y-110.36% ROI-124.05% 52W High-44.90% Beta1.12
Dividend TTM- Quick Ratio6.39 Sales past 5Y0.00% Gross Margin54.02% 52W Low450.00% ATR (14)0.78
Dividend Ex-Date- Current Ratio6.72 EPS Y/Y TTM-35.85% Oper. Margin-8183.04% RSI (14)83.59 Volatility13.86% 12.56%
Employees268 Debt/Eq4.39 Sales Y/Y TTM- Profit Margin-8449.76% Recom1.57 Target Price13.33
Option/ShortYes / Yes LT Debt/Eq4.37 EPS Q/Q44.68% Payout- Rel Volume0.71 Prev Close9.62
Sales Surprise15.78% EPS Surprise20.11% Sales Q/Q- EarningsFeb 27 BMO Avg Volume5.84M Price9.68
SMA2041.15% SMA50106.13% SMA20052.32% Trades Volume4,153,193 Change0.62%
Date Action Analyst Rating Change Price Target Change
Jan-03-24Upgrade Mizuho Neutral → Buy $4 → $8
Oct-26-23Downgrade Mizuho Buy → Neutral $57 → $4
Oct-13-23Downgrade Goldman Buy → Neutral $32 → $6
Sep-07-22Initiated Needham Buy $46
Mar-17-22Initiated Goldman Buy $45
Jun-30-21Initiated Mizuho Buy $58
May-27-21Upgrade Morgan Stanley Equal-Weight → Overweight $52
Nov-09-20Upgrade Goldman Neutral → Buy $34 → $36
Oct-08-20Initiated Truist Buy $38
Feb-25-20Initiated Guggenheim Buy $36
Feb-16-24 08:00AM
Feb-06-24 04:00PM
Feb-01-24 03:04PM
Jan-31-24 08:00AM
Jan-29-24 08:00AM
08:00AM Loading…
Jan-22-24 08:00AM
Jan-18-24 12:00PM
Jan-14-24 04:00AM
04:00AM
Dec-23-23 07:32PM
Dec-19-23 11:48AM
Dec-18-23 06:02AM
04:58AM
Dec-15-23 05:19PM
05:14PM
05:11PM Loading…
05:11PM
Dec-01-23 10:00PM
Nov-29-23 08:00AM
Nov-17-23 09:35AM
Nov-16-23 11:04PM
Nov-15-23 01:26PM
Nov-14-23 05:04PM
Nov-05-23 03:55PM
Nov-03-23 09:47AM
07:30AM
Nov-02-23 04:00PM
Nov-01-23 09:35AM
Oct-31-23 09:35AM
Oct-26-23 12:32PM
Oct-25-23 04:00PM
08:00AM Loading…
Oct-20-23 08:00AM
Oct-19-23 11:45PM
04:04PM
Oct-13-23 08:00AM
Oct-09-23 08:52AM
Oct-06-23 08:00AM
Oct-05-23 04:00PM
Sep-27-23 08:00AM
04:16AM
Sep-25-23 04:17PM
09:00AM
Sep-19-23 07:30AM
Sep-15-23 04:00PM
Sep-13-23 08:32AM
Sep-12-23 07:30AM
Sep-07-23 03:08PM
08:15AM
Sep-05-23 04:00PM
Aug-31-23 10:12PM
10:33AM
08:00AM
Aug-29-23 08:00AM
Aug-18-23 04:30PM
Aug-13-23 08:08AM
Aug-11-23 06:02AM
Aug-10-23 08:16AM
Aug-09-23 09:23AM
09:11AM
Aug-08-23 06:15PM
04:02PM
Aug-04-23 04:00PM
Jul-24-23 04:00PM
Jul-17-23 08:00AM
Jul-05-23 04:00PM
Jun-09-23 05:33PM
Jun-06-23 04:00PM
Jun-05-23 04:00PM
May-24-23 05:00PM
May-18-23 04:37PM
May-09-23 05:45PM
04:02PM
May-05-23 04:00PM
May-02-23 08:00AM
Apr-28-23 04:01PM
Apr-25-23 04:00PM
Apr-18-23 08:00AM
Apr-12-23 04:45PM
Apr-07-23 04:00PM
Apr-05-23 08:00AM
Mar-18-23 07:00AM
Mar-09-23 08:00AM
Mar-03-23 04:00PM
Mar-02-23 09:17PM
06:25AM
Mar-01-23 11:03AM
Feb-28-23 04:02PM
Feb-21-23 08:00AM
Feb-08-23 08:00AM
Feb-03-23 04:10PM
Jan-17-23 07:48AM
Jan-14-23 04:00AM
Jan-05-23 04:00PM
Dec-19-22 08:00AM
Dec-12-22 08:00AM
Dec-05-22 04:01PM
08:00AM
Dec-01-22 03:00PM
Nov-28-22 08:00AM
Nov-21-22 09:15AM
Nov-17-22 08:00AM
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Burnett PatrickSee RemarksJan 02Sale3.541,3254,69257,032Jan 03 05:30 PM
Watanabe Todd FranklinSee RemarksDec 01Option Exercise1.6859,525100,038513,682Dec 01 08:51 PM
Matsuda MasaruSee RemarkNov 21Sale1.981,8503,66146,634Nov 21 05:47 PM
Frazier Life Sciences VIII, L.10% OwnerOct 24Buy2.5080,000200,0008,764,232Oct 26 04:09 PM
Burnett PatrickSee RemarksAug 21Sale7.041,60511,30258,357Aug 22 12:24 PM
Watanabe Todd FranklinSee RemarksMay 31Buy6.381,4639,334515,145Dec 01 08:51 PM
Matsuda MasaruSee RemarkMay 31Sale7.801,83014,27842,146Jun 02 08:31 PM
Welgus Howard G.DirectorApr 17Option Exercise1.688,50014,285174,325Apr 18 07:00 PM
Welgus Howard G.DirectorApr 17Sale13.978,500118,728165,825Apr 18 07:00 PM
Welgus Howard G.DirectorApr 06Option Exercise1.688,50014,285174,325Apr 10 04:13 PM
Welgus Howard G.DirectorApr 06Sale12.018,500102,085165,825Apr 10 04:13 PM
Watanabe Todd FranklinSee RemarksMar 06Sale15.262,43537,167366,657Mar 08 04:29 PM
Burnett PatrickSee RemarksMar 06Sale15.2685112,98959,962Mar 08 04:28 PM
Lock Kenneth A.Chief Commercial OfficerMar 06Sale15.2683112,68463,429Mar 08 04:25 PM
Turney Patricia A.SVP, OperationsMar 06Sale15.2683112,68462,862Mar 08 04:26 PM
OSBORNE DAVID WChief Technical OfficerMar 06Sale15.2669010,532268,854Mar 08 04:26 PM
Burrows Scott LChief Financial OfficerMar 06Sale15.262914,44259,115Mar 08 04:29 PM
Watanabe Todd FranklinSee RemarksMar 02Sale15.835,47286,606369,092Mar 02 07:06 PM
Burnett PatrickSee RemarksMar 02Sale15.831,75127,71339,813Mar 06 06:51 PM
Moore Matthew RichardSee RemarksMar 02Sale15.831,61025,48111,690Mar 06 06:54 PM
Burrows Scott LChief Financial OfficerMar 02Sale15.831,43422,69638,406Mar 02 07:05 PM
Matsuda MasaruSee RemarksMar 02Sale15.831,43422,69618,101Mar 06 06:52 PM
Turney Patricia A.SVP, OperationsMar 02Sale15.831,43222,66445,693Mar 02 07:07 PM
Lock Kenneth A.Chief Commercial OfficerMar 02Sale15.831,43222,66443,260Mar 02 07:04 PM
OSBORNE DAVID WChief Technical OfficerMar 02Sale15.831,21319,198254,644Mar 02 07:03 PM
Watanabe Todd FranklinSee RemarksFeb 28Sale16.172,34337,878374,564Mar 02 07:06 PM
Turney Patricia A.SVP, OperationsFeb 28Sale16.1793615,13247,125Mar 02 07:07 PM
Lock Kenneth A.Chief Commercial OfficerFeb 28Sale16.1793615,13244,692Mar 02 07:04 PM
OSBORNE DAVID WChief Technical OfficerFeb 28Sale16.1779212,804255,857Mar 02 07:03 PM
Burrows Scott LChief Financial OfficerFeb 28Sale16.174166,72539,840Mar 02 07:05 PM